blincyto - blinatumomab
(Blinatumomab)Amgen, Inc
Usage: BLINCYTO is indicated for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in various stages, including first or second complete remission with minimal residual disease, relapsed or refractory disease, and during the consolidation phase of chemotherapy.